In this preclinical study, we investigated combination therapy with small-molecule inhibitors of AKT and HER2 to overcome limitations associated with anti-HER2 monotherapy in HER2+ breast cancer cell lines with PIK3CA mutations. This evidence concerns the gene PIK3CA and breast cancer.